Our systematic review aimed to evaluate the efficacy of currently available GLP‐1 RAs (Table 1) in the management of NAFLD, the degree of heterogeneity in trial design and the robustness of conclusions drawn from these clinical trials. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.